Mallory Burns

Mallory Burns

Auto-generated profile, based on publicly available information

Mallory Burns

University of Florida

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SBS. Mallory Burns
S. Mallory Burns
Christopher W. CunninghamChristopher W. Cunningham
Christopher W. Cunningham
SMSusan L. Mercer
Susan L. Mercer

26 August 2017 in Mycotoxin Research
Verified
Journal Article
Closed access
PDF file
Ankit PatrasAnkit Patras
Ankit Patras
SJSharath Julakanti
Sharath Julakanti
SYSudheer Yannam
Sudheer Yannam
RBRishipal R. Bansode
Rishipal R. Bansode
MBMallory Burns
Mallory Burns
MVMatthew J. Vergne
Matthew J. Vergne

1 September 2018 in LWT
Verified
Journal Article
Closed access
VGVybhav Vipul Sudhir Gopisetty
Vybhav Vipul Sudhir Gopisetty
Ankit PatrasAnkit Patras
Ankit Patras
AKAgnes Kilonzo-Nthenge
Agnes Kilonzo-Nthenge
SYSudheer Yannam
Sudheer Yannam
RBRishipal R. Bansode
Rishipal R. Bansode
HXHang Xiao
Hang Xiao

18 April 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SOSamuel Obeng
Samuel Obeng
APAvi Patel
Avi Patel
MBMallory Burns
Mallory Burns
SISebastiano Intagliata
Sebastiano Intagliata
Marco MottinelliMarco Mottinelli
Marco Mottinelli
THTakato Hiranita
Takato Hiranita
Opioid overdose is one of the leading causes of death in the United States in people under 50 years, which has resulted in a decline in life expectancy in the United States. Thus, there is a need for an alternative to prescription mu‐opioid agonists for pain treatment. Delta (9)‐tetrahydrocannabinol (THC), a cannabinoid (CB) agonist, has been shown to produce antinociceptive effects albeit less effectively than mu‐opioid receptor agonists. Sigma 1 receptor (σ 1 R) antagonists in combination with THC may provide a viable and safe pharmacological alternative to prescription opioids for pain treatment. The present study compared the pharmacological effects of the σ 1 R antagonist CM304 alone and in combination with THC in Sprague Dawley rats. Hotplate latency was determined at 52°C followed by rectal temperature measurement and the drugs were administered intravenously (i.v.) and in cumulative doses every 5 min. THC dose‐dependently increased maximum possible effects (MPEs) up to 84% which were reversed by 10 mg/kg rimonabant (cannabinoid CB 1 receptor antagonist). CM304 alone up to a dose of 10 mg/kg did not produce significant antinociceptive or hypothermic effects, but CM304 (1.0 and 3.2 mg/kg, i.v.) dose‐dependently left‐shifted the dose‐effect functions of the antinociceptive (7.3‐fold at 3.2 mg/kg CM304) and hypothermic effects of THC. In rats discriminating 3.2 mg/kg THC i.p. from vehicle under a fixed ratio (FR) 10 schedule of food delivery, the cannabinoid CB 1 receptor agonist CP55,940 fully substituted for THC, whereas CM304 i.p. produced a maximum of 27 % THC‐lever responding at 17.8 mg/kg. CM304, at doses of 32 and 56 mg/kg, decreased response rate to 24 and 9 %, respectively. No dose of BD1063 (σ 1 R antagonist), rimonabant, SR144528 (cannabinoid CB 2 receptor antagonist), morphine (μ‐opioid receptor agonist), or naltrexone (opioid antagonist) produced greater than 30% THC‐lever responding. Pretreatment with rimonabant (1.78 mg/kg) produced a rightward shift in the dose effect curve of THC (4.5‐fold) and CP55940 (4.5‐fold) while pretreatment with CM304, BD1063, SR144528, and naltrexone had no significant effect on the dose effect curve of THC. The present results may support the development of a σ 1 R antagonist as an adjunct to cannabinoids for treatment of acute pain without enhancing an undesirable side effect of THC. Support or Funding Information: This work was supported by National Institute on Drug Abuse grants DA23205 and DA48353.

18 April 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
APAvi Patel
Avi Patel
SOSamuel Obeng
Samuel Obeng
MBMallory Burns
Mallory Burns
SISebastiano Intagliata
Sebastiano Intagliata
Marco MottinelliMarco Mottinelli
Marco Mottinelli
THTakato Hiranita
Takato Hiranita
There is an overdose epidemic associated with the use of illicitly manufactured as well as prescription mu‐opioid receptor agonists. Sigma 1 receptor (σ 1 R) antagonists in combination with other drugs may provide a viable, safer pharmacological option than opioids alone for treating pain. The present study compared pharmacological effects of the σ 1 R antagonist CM304 alone and in combination with high (fentanyl and morphine) and low (buprenorphine) efficacy opioid agonists and the cannabinoid CB (CP55,940 and THC) receptor agonists in C57BL/6J mice. Rectal temperature, tail withdrawal latency (10‐seconds cutoff) from warm water of various temperatures (45°C, 50°C and 55°C) and counts of unhabituated locomotor activity were measured in this order. Basal latency for tail withdrawal systematically decreased from 10 seconds at 45°C to 1.3 seconds at 55°C. Morphine, fentanyl and buprenorphine dose‐dependently increased maximum possible effects (MPEs) up to 100% at 55°C (ED 50 values: 7.50, 0.068, and 1.13 mg/kg, respectively), whereas CP55,940 and THC were less effective at 55°C (E max values: 56.6% and 58.2%, respectively). CM304 (56 mg/kg, i.p.) produced an upward shift in the CP55,940 dose‐effect function such that 100% MPE was achieved at 3.2 mg/kg CP55,940, while CM304 (56 mg/kg) produced a 3‐fold leftward shift in the dose‐effect curve of THC. On the other hand, CM304 did not enhance the antinociceptive effects of morphine and fentanyl but enhanced the effects of buprenorphine. In contrast to tail withdrawal latency, there were no consistent effects of CM304 on cannabinoid‐induced decreases in rectal temperature or locomotor activity. The present results may support the development of a σ 1 R antagonist as an adjunct to cannabinoid and low efficacy μ‐opioid receptor agonists for the treatment of acute pain. Support or Funding Information: This work was supported by National Institute on Drug Abuse grants DA23205 and DA48353.